Shares of Arrowhead Research Corp. (NASDAQ:ARWR) shot up 2.1% during trading on Tuesday . The company traded as high as $6.30 and last traded at $6.25, with a volume of 396,671 shares traded. The stock had previously closed at $6.12.

A number of brokerages recently commented on ARWR. Vetr lowered Arrowhead Research Corp. from a “buy” rating to a “hold” rating and set a $6.49 price objective for the company. in a research report on Tuesday, April 19th. Piper Jaffray Cos. reduced their target price on Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating on the stock in a report on Wednesday, August 10th. Jefferies Group restated a “hold” rating and set a $4.75 target price on shares of Arrowhead Research Corp. in a report on Wednesday, May 11th. Finally, Chardan Capital assumed coverage on Arrowhead Research Corp. in a report on Thursday, May 19th. They set a “buy” rating and a $12.00 target price on the stock. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $9.53.

The stock has a 50-day moving average price of $5.73 and a 200 day moving average price of $5.21. The company’s market cap is $374.83 million.

Arrowhead Research Corp. (NASDAQ:ARWR) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.05. The business had revenue of $39.58 million for the quarter, compared to the consensus estimate of $0.05 million. Arrowhead Research Corp.’s quarterly revenue was down 68.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.27) earnings per share. On average, equities analysts expect that Arrowhead Research Corp. will post ($1.30) EPS for the current year.

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.